294 related articles for article (PubMed ID: 23834553)
1. Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients.
Kalkavoura CS; Michopoulos I; Arvanitakis P; Theodoropoulou P; Dimopoulou K; Tzebelikos E; Lykouras L
Exp Clin Psychopharmacol; 2013 Aug; 21(4):332-41. PubMed ID: 23834553
[TBL] [Abstract][Full Text] [Related]
2. Cabergoline-induced psychotic exacerbation in schizophrenic patients.
Chang SC; Chen CH; Lu ML
Gen Hosp Psychiatry; 2008; 30(4):378-80. PubMed ID: 18585544
[TBL] [Abstract][Full Text] [Related]
3. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study.
Cavallaro R; Cocchi F; Angelone SM; Lattuada E; Smeraldi E
J Clin Psychiatry; 2004 Feb; 65(2):187-90. PubMed ID: 15003071
[TBL] [Abstract][Full Text] [Related]
4. The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine.
Nakonezny PA; Byerly MJ; Rush AJ
J Sex Marital Ther; 2007; 33(3):203-16. PubMed ID: 17454518
[TBL] [Abstract][Full Text] [Related]
5. Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia.
Konarzewska B; Wołczyński S; Szulc A; Galińska B; Popławska R; Waszkiewicz N
Psychoneuroendocrinology; 2009 Jan; 34(1):129-39. PubMed ID: 18838228
[TBL] [Abstract][Full Text] [Related]
6. Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride.
Kim EY; Kim SH; Lee NY; Jung DC; Kim YS; Ahn YM
Pharmacopsychiatry; 2012 Mar; 45(2):57-63. PubMed ID: 22411694
[TBL] [Abstract][Full Text] [Related]
7. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.
Chen CK; Huang YS; Ree SC; Hsiao CC
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1495-9. PubMed ID: 20732372
[TBL] [Abstract][Full Text] [Related]
8. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
[TBL] [Abstract][Full Text] [Related]
9. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.
Tollin SR
J Endocrinol Invest; 2000 Dec; 23(11):765-70. PubMed ID: 11194712
[TBL] [Abstract][Full Text] [Related]
10. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.
Cohen LG; Biederman J
J Child Adolesc Psychopharmacol; 2001; 11(4):435-40. PubMed ID: 11838826
[TBL] [Abstract][Full Text] [Related]
11. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
Chen JX; Su YA; Bian QT; Wei LH; Zhang RZ; Liu YH; Correll C; Soares JC; Yang FD; Wang SL; Zhang XY
Psychoneuroendocrinology; 2015 Aug; 58():130-40. PubMed ID: 25981348
[TBL] [Abstract][Full Text] [Related]
12. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Lu ML; Shen WW; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
[TBL] [Abstract][Full Text] [Related]
13. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia.
Yuan HN; Wang CY; Sze CW; Tong Y; Tan QR; Feng XJ; Liu RM; Zhang JZ; Zhang YB; Zhang ZJ
J Clin Psychopharmacol; 2008 Jun; 28(3):264-370. PubMed ID: 18480682
[TBL] [Abstract][Full Text] [Related]
14. Biological response modifiers of cancer-related neuroendocrine disorders: efficacy of the long-term dopaminergic agonist cabergoline in the treatment of breast cancer-induced hyperprolactinemia.
Lissoni P; Vaghi M; Pescia S; Rovelli F; Ardizzola A; Valtulina F; Malugani F; Gardani G; Tancini G
J Biol Regul Homeost Agents; 2004; 18(3-4):291-4. PubMed ID: 15786695
[TBL] [Abstract][Full Text] [Related]
15. Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial.
Byerly MJ; Nakonezny PA; Rush AJ
Psychiatry Res; 2008 May; 159(1-2):115-20. PubMed ID: 18295343
[TBL] [Abstract][Full Text] [Related]
16. [Risperidone-induced symptomatic hyperprolactinemia in youth with schizophrenia: efficacy and tolerability of cabergoline treatment].
Pollice R; Di Giovambattista E; Tomassini A; Di Pucchio A; Mazza M; Di Michele V; Roncone R; Casacchia M
Clin Ter; 2007; 158(2):121-6. PubMed ID: 17566512
[TBL] [Abstract][Full Text] [Related]
17. Cabergoline: long-acting oral treatment of hyperprolactinemic disorders.
Ferrari C; Mattei A; Melis GB; Paracchi A; Muratori M; Faglia G; Sghedoni D; Crosignani PG
J Clin Endocrinol Metab; 1989 Jun; 68(6):1201-6. PubMed ID: 2656736
[TBL] [Abstract][Full Text] [Related]
18. Recurrence of hyperprolactinemia and continuation of ovarian acyclicity in captive African elephants (Loxodonta africana) treated with cabergoline.
Morfeld KA; Ball RL; Brown JL
J Zoo Wildl Med; 2014 Sep; 45(3):569-76. PubMed ID: 25314824
[TBL] [Abstract][Full Text] [Related]
19. Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients.
Mattei AM; Ferrari C; Baroldi P; Cavioni V; Paracchi A; Galparoli C; Romano C; Spellecchia D; Gerevini G; Crosignani PG
J Clin Endocrinol Metab; 1988 Jan; 66(1):193-8. PubMed ID: 3275684
[TBL] [Abstract][Full Text] [Related]
20. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine.
De Rosa M; Colao A; Di Sarno A; Ferone D; Landi ML; Zarrilli S; Paesano L; Merola B; Lombardi G
Eur J Endocrinol; 1998 Mar; 138(3):286-93. PubMed ID: 9539303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
